Skip to main
MEDP
MEDP logo

Medpace Holdings (MEDP) Stock Forecast & Price Target

Medpace Holdings (MEDP) Analyst Ratings

Based on 11 analyst ratings
Hold
Strong Buy 0%
Buy 9%
Hold 64%
Sell 9%
Strong Sell 18%

Bulls say

Medpace Holdings anticipates a significant increase in passthrough revenues, projecting a rise of 200-300 basis points in the second half of the year compared to elevated levels observed in the second quarter. Additionally, the company reported strong demand indicators with higher RFP (Request for Proposal) volume in the first quarter, suggesting increased market activity. Furthermore, Medpace expects its book-to-bill ratio to recover above 1.15x in the third quarter, indicating robust growth potential and demand for its clinical trial services.

Bears say

Medpace Holdings has experienced higher-than-normal backlog cancellations, which have only recently begun to decline toward the lower end of its expected range, indicating potential instability in client demand. The company has expressed uncertainty regarding the growth of its Direct Service revenue, which it deems too early to quantify, suggesting challenges in revenue forecasting. Additionally, despite upward revisions in adjusted EBITDA estimates for 2025 and 2026, the continued hiring in direct service costs and anticipated declines in passthrough revenues raise concerns about profitability and operational efficiency moving forward.

Medpace Holdings (MEDP) has been analyzed by 11 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 9% recommend Buy, 64% suggest Holding, 9% advise Selling, and 18% predict a Strong Sell.

This aggregate rating is based on analysts' research of Medpace Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Medpace Holdings (MEDP) Forecast

Analysts have given Medpace Holdings (MEDP) a Hold based on their latest research and market trends.

According to 11 analysts, Medpace Holdings (MEDP) has a Hold consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $465.18, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $465.18, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Medpace Holdings (MEDP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.